Studies on lipidomimetic derivatives of α-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model

Parasite

Volumn 5, Issue 3, 1998, Pages 239-246

  Loiseau, P M ^a   Czok, M ^a   Chauffert, O ^a   Bourass, J ^b   Letourneux, Y ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ DE LA ROCHELLE   (France)

Author keywords

Antitrypanosomal compounds; Lipidomimetic derivatives; Trypanosoma brucei brucei; difluoromethylornithine

Indexed keywords

MURINAE; TRYPANOSOMA; TRYPANOSOMA BRUCEI BRUCEI;

ANTITRYPANOSOMAL AGENT; DRUG DERIVATIVE; EFLORNITHINE; ESTERASE; PRODRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL; ARTICLE; BIOAVAILABILITY; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFECT; DRUG STABILITY; FEMALE; LD 50; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PERITONEUM MACROPHAGE; TRYPANOSOMA BRUCEI;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CULTURE MEDIA; DISEASE MODELS, ANIMAL; DRUG STABILITY; EFLORNITHINE; ESTERASES; FEMALE; LETHAL DOSE 50; MACROPHAGES, PERITONEAL; MICE; PRODRUGS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 0032158732     PISSN: 1252607X     EISSN: None     Source Type: Journal    
DOI: 10.1051/parasite/1998053239     Document Type: Article

References (17)

1. BACCHI C.J., NATHAN H.C., YARLETT N., GOLDBERG B., MCCANN P.P., SJOERDSMA A. et al. Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-a-difluoromethylornithine and standard trypanocides. Antimicrobial Agents and Chemotherapy, 1994, 38, 563-569.
2. BAYLES J.D., HARRISON S.M., MBWABI D.L. & SCHECHTER P.J. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Annals of Tropical Medicine and Parasitology, 1989, 83, 111-114.
3. CLARKSON A.B., BIENEN E.J., BACCHI C.J., MCCANN P.P., NATHAN H.C., HUTNER S.H. et al. New drug combination for experimental late-stage African trypanosomiasis: DFMO with suramine. American Journal of Tropical Medicine and Hygiene, 1984, 33, 1073-1077.
4. DEVERRE J.R., LOISEAU P.M., COUVREUR P., LETOURNEUX Y., GAYRAL P. & BENOIT J.P. In vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: a diglyceride prodrug. Journal of Pharmacy and Pharmacology 1989, 41, 191-193.
5. DOUA F., BOA F.Y., SCHECHTER P.J., MIEZAN T.W., DIAI D., SANON F.R. et al L'alpha-difluorométhylornithine (Eflornithine) dans le traitement de la trypanosomiase humaine africaine à T. gambiense au stade tardif: efficacité et tolérance. Bulletin de la Société de Pathologie Exotique et de ses Filiales, 1988, 81, 589-590.
6. ELKIHEL L., LOISEAU P.M., BOURASS J., GAYRAL P. & LETOURNEUX Y. Synthesis and orally macrofilaricidal evaluation of niclosamide lymphotropic prodrugs. Arzneimittel Forschung/Drug Research, 1994, 44, 1259-1264.
7. HAEGELE K.D., ALKEN R.G., GROVE J., SCHECHTER P.J. & KOCHWESER J. Kinetics of DFMO: an irreversible inhibition of ornithine decarboxylase. Clinical and Pharmacological Therapeutics, 1981, 30, 210-217.
8. JENNINGS F.W. Relative efficacy of melarsen oxide compared with mel Cy (Cymelarsan) when used in combination with difluoromethylornithine in the treatment of trypanosomiasis of the central nervous system. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 257-258.
9. KAMINSKY R., GUMM I.D., ZWEYGARTH E. & CHUMA F. A drug incubation infectivity test (DIIT) for assessing resistance in trypanosomes. Veterinary Parasitology, 1990, 34, 335-343.
10. LEVIN V.A., CSEJTEY J. & BYRD D.J. Brain, CSF, and tumor pharmacokinetics of a-difluoromethylornithine in rats and dogs. Cancer Chemotherapy and Pharmacology, 1983, 10, 196-199.
11. LOISEAU P.M., WOLF J.G. & GAYRAL P. Spiroarsoranes of second generation: evaluation of trypanocidal properties against Trypanosoma brucei brucei. Tropical Medicine and Parasitology, 1993, 44, 37-36.
12. LOISEAU P.M., DEVERRE J.R., ELKIHEL L., GAYRAL P. & LETOURNEUX Y. Study of lymphotropic targeting and macrofilaricidal activity of a melphalan prodrug on the Molinema dessetae model. Journal of Chemotherapy, 1994, 6, 230-237.
13. LOISEAU P.M., BOURASS J. & LETOURNEUX Y. Lymphotropic anti-filarial agents derived from closantel and chlorambucil. International Journal for Parasitology, 1997a, 27, 443-447.
14. LOISEAU P.M., CHAUFFERT O. & CZOK M. Effect of chronic trypanosomiasis on the bioavailability of a-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. Parasitology Research, 1997b, 83, 386-389.
15. MOSMANN T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 1983, 65, 55-63.
16. SIMARRO P.P. & NDONG ASUMU Gambian trypanosomiasis and synergism between melarsoprol and eflornithine: first case report. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 315.
17. VAN NIEUWENHOVE S. Advances in sleeping sickness therapy. Annales de la Société Belge de Médecine Tropicale, 1992, 72, 39-51.